Back to News
Market Impact: 0.25
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Source: 247wallst.com
Healthcare & BiotechCorporate EarningsCompany FundamentalsInvestor Sentiment & Positioning
Full late-stage results for Moderna and Merck’s personalized melanoma vaccine were positive, but the figures fell short of the highest expectations built into a prior long rally. Selling continued despite the positive results; the article provides no specific figures or share-price changes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.05
Ticker Sentiment
MRK0.20
MRNA0.20
More News
- Next week brings major risks for the stock market, just as the AI trade keeps faltering
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Investing.com’s stocks of the week
- Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
- Moderna Stock Cools After Cancer Vaccine Data Leak
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts
- How to Automate Equity Research Workflows: A Control-First Guide